Jun 1, 2026
Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business for Up to $2.65 Billion
French pharmaceutical company Servier will acquire Edgewise Therapeutics' experimental muscular dystrophy drug and related business for up to $2.65 billion. Edgewise will pivot to focus on cardiovascular drugs following the transaction.
2 sources
00